- Conditions
- Overactive Bladder Syndrome
- Interventions
- Vaginal estrogen, Mirabegron 50 MG [Myrbetriq]
- Drug
- Lead sponsor
- Walter Reed National Military Medical Center
- Federal
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 152 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 217–240
of 288
matching trials from the live ClinicalTrials.gov search.
- Conditions
- HR+/HER2- Breast Cancer, HR+, HER2-, Advanced Breast Cancer
- Interventions
- AVZO-021, Fulvestrant, Letrozole, AVZO-023
- Drug
- Lead sponsor
- Avenzo Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 380 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 16
- States / cities
- Los Angeles, California • New Haven, Connecticut • Orlando, Florida + 12 more
- Conditions
- Vulvovaginal Atrophy
- Interventions
- Vehicle, WC3011 Estradiol Vaginal Cream
- Drug
- Lead sponsor
- Warner Chilcott
- Industry
- Eligibility
- 35 Years and older · Female only
- Enrollment
- 576 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 48
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Phoenix, Arizona + 38 more
- Conditions
- Breast Cancer, Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, HR-positive Breast Cancer, HR+/HER2- Breast Cancer, Locally Advanced Breast Cancer, Metastatic Breast Cancer
- Interventions
- PRT13722, Fulvestrant, Abemaciclib, Imlunestrant
- Drug
- Lead sponsor
- Prelude Therapeutics Incorporated
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 242 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 3
- States / cities
- Tamarac, Florida • Maumee, Ohio • Fairfax, Virginia
- Conditions
- Parkinson's Disease
- Interventions
- Premarin ®
- Drug
- Lead sponsor
- The Parkinson Study Group
- Network
- Eligibility
- Up to 75 Years · Female only
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2006
- U.S. locations
- 6
- States / cities
- Sunnyvale, California • Atlanta, Georgia • Indianapolis, Indiana + 3 more
- Conditions
- Atherosclerosis
- Interventions
- 17B-estradiol, Placebo
- Drug · Other
- Lead sponsor
- University of Southern California
- Other
- Eligibility
- Female only
- Enrollment
- 643 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2004 – 2013
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Menopausal Complaints, Vaginal Atrophy, Genitourinary Symptoms, HIV (Human Immunodeficiency Virus), Menopause Related Conditions, Vaginitis, Perimenopause
- Interventions
- Vaginal estradiol tablets, Vaginal moisturizer
- Drug · Other
- Lead sponsor
- Albert Einstein College of Medicine
- Other
- Eligibility
- 40 Years to 70 Years · Female only
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
- Interventions
- Estradiol vaginal cream
- Drug
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 11 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Coronary Disease, Cardiovascular Diseases, Heart Diseases, Neurologic Manifestations
- Interventions
- Estrogen Replacement Therapy, Surgery
- Drug · Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2005
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Heart Disease
- Interventions
- 0.625 mg of conjugated equine estrogen, 0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate, placebo tablets
- Drug
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 55 Years and older · Female only
- Enrollment
- 309 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Obesity
- Interventions
- leuprolide acetate, Estradiol Transdermal, progressive resistance exercise training
- Drug · Behavioral
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 79 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2014
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Adolescent Development, Stress, Emotional Disturbances
- Interventions
- Trier Social Stress Test, Emotional go/no-go task
- Behavioral
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 11 Years to 14 Years · Female only
- Enrollment
- 53 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Menopause, Arteriosclerosis
- Interventions
- Conjugated equine estrogens 0.45 mg/day, Transdermal estradiol, 50 mcg/day, Micronized progesterone, 200 mg/day x 12 d/month, CEE , progesterone, estradiol patch or placebo for each, CEE, progesterone, transdermal patch or the placebo
- Drug
- Lead sponsor
- Kronos Longevity Research Institute
- Other
- Eligibility
- 42 Years to 58 Years · Female only
- Enrollment
- 728 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2012
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • San Francisco, California • New Haven, Connecticut + 6 more
- Conditions
- Advanced or Metastatic Breast Cancer
- Interventions
- PF-07220060 CDK4 inhibitor, Fulvestrant, Everolimus, Exemestane
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 333 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 9
- States / cities
- Irvine, California • Los Angeles, California • Newport Beach, California + 3 more
- Conditions
- Vaginal Atrophy
- Interventions
- Bazedoxifene/Conjugated Estrogen
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 650 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 63
- States / cities
- Birmingham, Alabama • Montgomery, Alabama • Scottsdale, Arizona + 60 more
- Conditions
- Menopause
- Interventions
- Premarin® (oral) vs. Alora® (transdermal)
- Drug
- Lead sponsor
- Watson Pharmaceuticals
- Industry
- Eligibility
- 42 Years to 70 Years · Female only
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- Started 2002
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Postmenopause
- Interventions
- 0.25mg DRSP / 0.5mg E2 (BAY86-4891), 0.5mg NETA / 1.0mg E2 (Activella)
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 40 Years to 65 Years · Female only
- Enrollment
- 662 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2009
- U.S. locations
- 17
- States / cities
- Chandler, Arizona • San Diego, California • Denver, Colorado + 13 more
- Conditions
- Menopause
- Interventions
- esterified estrogens 0.625 mg and methyltestosterone 1.25 mg
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 30 Years to 65 Years · Female only
- Enrollment
- 350 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2007
- U.S. locations
- 77
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Montgomery, Alabama + 74 more
- Conditions
- Menopause, Postmenopause
- Interventions
- Estrogen
- Drug
- Lead sponsor
- National Center for Research Resources (NCRR)
- NIH
- Eligibility
- 35 Years to 75 Years · Female only
- Enrollment
- 15 participants
- Healthy volunteers
- Accepts healthy volunteers
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Menopause, Prediabetes, Obesity
- Interventions
- Placebo, conjugated estrogens/bazedoxifene (CE/BZA)
- Other · Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years to 60 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- New Orleans, Louisiana
- Conditions
- Breast Cancer
- Interventions
- Fulvestrant, Anastrozole, Everolimus, Placebo - Anastrozole, Placebo - Everolimus
- Drug
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2019
- U.S. locations
- 223
- States / cities
- Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 150 more
- Conditions
- Alzheimer Disease
- Interventions
- Transdermal estradiol, Medroxyprogesterone, Placebo Patch, Placebo
- Drug
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 55 Years to 90 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2007
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Primary Ovarian Insufficiency, Premature Menopause, Metabolic Complications, Endothelial Function (FMD), Estrogen Replacement Therapy
- Interventions
- Not listed
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 30 Years to 40 Years · Female only
- Enrollment
- 45 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Major Depressive Disorder
- Interventions
- Transdermal estradiol, Progesterone, Transdermal placebo patch, placebo capsule
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina